Business Wire

Erbe introduces VIO® 3n & VIO® seal: Tailored electrosurgical generators for high-performance workflows

25.4.2025 09:00:00 CEST | Business Wire | Press Release

Share

With the introduction of the VIO® 3n, Erbe Elektromedizin GmbH expands its established VIO® 3 family with a new generation of electrosurgical generators, specifically tailored to different medical specialties and procedural requirements. The portfolio is further enhanced by the VIO® seal, the first VIO® generator fully dedicated to bipolar applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425843193/en/

VIO 3n Fire

Five configurations for precise surgical and endoscopic applications

With over 100 years of experience in electrosurgery, Erbe continues to innovate with the introduction of five new VIO® 3n configurations: Fire, Water, Metal, Timber, and Stone. Each configuration is designed to meet the unique demands of different surgical and endoscopic procedures, providing preprogrammed CUT, COAG, and dissection settings that enhance efficiency and reduce complexity. The VIO® 3n features trusted Erbe electrosurgical modes such as endoCUT®, preciseSECT, and pulsedAPC, ensuring reproducible tissue effects across specialties, also introducing our new mode endoCUT® U, developed for “underwater” applications.

Beyond precise tissue effect adjustment, the VIO® 3n prioritizes intuitive usability: its interface with stepGUIDE supports surgical teams with logical menu navigation and real-time notifications, simplifying setup and operation. Additionally, the generator seamlessly integrates with other Erbe units, such as APC 3 and IES 3, as well as Erbe instruments and accessories allowing flexible adaptation to existing workstations.

VIO® seal: The first VIO® generator for bipolar applications

As a specialized solution for bipolar electrosurgical procedures, the VIO® seal is a significant addition to the Erbe portfolio. Designed for use with TriSect rapide®, BiClamp® and standard bipolar instruments, the unit can function as a standalone solution or in combination with the VIO® 3n as well as existing installed bases like the VIO® D and S series. Featuring digital instrument recognition, it aligns perfectly with surgical workflows.

A key feature: when paired with another VIO® generator, the VIO® seal enables simultaneous bipolar activation, expanding the possibilities of surgical procedures.

A future-proof electrosurgical solution built to fit various clinical demands

With the launch of the VIO® 3n and VIO® seal, Erbe takes another step toward becoming a comprehensive solution provider. The combination of tailored configurations, high-performance workflows, and trusted Erbe technology creates a platform designed to meet the specific needs of various medical specialties.

“After more than 100 years of electrosurgery and over 100,000 VIO® electrosurgical generators sold, Erbe is launching the next generation – the VIO® 3n,” explains Dr. Helmut Scherer, Chief Technology Officer of the Erbe Group. “With the VIO® 3n, the successful operating concept of the VIO® 3 is transferred to the next technology generation and made available for various medical disciplines.”

The new systems will be available in the CE market and CE related countries from April 2025.

About Erbe Elektromedizin

Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OR teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.

Fields of activity

  • Imaging
  • Endoscopy
  • Electrosurgery
  • Plasma surgery
  • Thermofusion
  • Hydrosurgery
  • Cryo technology

An international network

  • 20 international sales and service units
  • 5 production sites
  • Erbe is active in 110 international markets.

The Erbe workforce

  • 2,100 employees worldwide
  • Some 1,100 of them in Germany

View source version on businesswire.com: https://www.businesswire.com/news/home/20250425843193/en/

Contacts

Erbe Elektromedizin GmbH
Waldhoernlestrasse 17
72072 Tuebingen
erbe-med.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.erbe-med.co
m%2F&esheet=54239766&newsitemid=20250425843193&lan=en-US&anchor=erbe-med.com&ind
ex=1&md5=388b47eab0c5becafa55f448f8f57000
info@erbe-med.com

David Malecki
Phone +49 7071 755-316
david.malecki@erbe-med.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye